MedTrace Logo

Losartan Effects on Emphysema Progression

NCT02696564 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2022-06-01

Study results available
· View outcomes & findings →

Summary

A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo

.

Conditions

  • Emphysema

Interventions

DRUG

Losartan

50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated

DRUG

Placebo

one capsule per day for two weeks, followed by two capsules per day for 46 weeks

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • JHSPH Center for Clinical Trials

    lead OTHER

Principal Investigators

  • Robert Wise, MD · Johns Hopkins University

  • Janet Holbrook, PhD · Johns Hopkins University Bloomberg School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-23
Primary Completion
2021-03-31
Completion
2021-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02696564 on ClinicalTrials.gov